Loading...
NPI 1891467643 · Boardman, OH · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Aura Genetics Of Ohio, LLC is a clinical medical laboratory provider located in Boardman, Ohio. This profile covers 9 Medicare and 16 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Aura Genetics Of Ohio, LLC |
| Address | 801 Kentwood Dr |
| City | Boardman |
| State | OH |
| ZIP | 44512 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 30, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $17.9M |
| Medicaid | $28.4K |
AURA GENETICS OF OHIO, LLC’s Medicare revenue is overwhelmingly driven by a single service line: K1034 (provision of nonprescription, self‑administered/self‑collected COVID‑19 tests). That code accounts for $18.2M in Medicare revenue and 1.5M claims, representing 99.7% of this provider’s total Medicare revenue and making the practice appear to operate largely as a high‑volume COVID self‑test channel on the Medicare side rather than a broad clinical genetics lab operation.
The provider’s Medicare revenue is extremely concentrated: the precomputed top‑3 Medicare codes account for 99.8% of Medicare revenue. Outside of K1034 the remaining Medicare codes (e.g., 81226, 81306 and other genetic tests) contribute only nominal dollars ($13.3K, $9.2K, etc.), indicating ancillary pharmacogenomic and HLA testing lines that do not materially move Medicare revenue.
K1034 is a national outlier for Medicare volume: this provider ranks #21 of 30143 providers nationally for K1034 (100th percentile) and is explicitly labeled an "extreme outlier, far above typical national volume for this code." By contrast, the genetics codes that appear on Medicare are at modest national ranks and are described as "typical, unremarkable volume for this code," signaling market dominance only in COVID self‑test provisioning, not in specialty genetic testing.
Payer mix is highly skewed to Medicare in scale: lifetime Medicare revenue is $17.9M versus lifetime Medicaid revenue of $28.4K, so Medicaid represents only a very small fraction of this provider’s lifetime billing footprint. This makes AURA GENETICS effectively a Medicare‑scale billing entity with minimal financial exposure to Medicaid volume and reimbursement dynamics.
Medicaid billing is more diversified but small in absolute terms: the precomputed top‑3 Medicaid codes account for 45.3% of Medicaid revenue, led by U0003 at $7.1K (25.6% of Medicaid revenue), 81226 at $3K (11.0%), and K1034 at $2.4K (8.7%). These Medicaid top codes are described as "typical, unremarkable volume" in‑state (for example U0003 ranks #108 of 141, 23th percentile), indicating the practice is a modest state‑level participant rather than a dominant Medicaid lab vendor.
Competitive standing differs sharply by payer: nationally the provider is a major, extreme outlier for K1034 on Medicare (rank #21 of 30143; 100th percentile), while for most genetic testing CPTs it occupies low to moderate national ranks (examples include 81226 at #53 of 77, 30th percentile; 81306 at #2 of 4, 67th percentile). On Medicaid the provider’s ranks are generally modest or low in‑state (e.g., U0003 #108 of 141, 23th percentile; several genetic codes are #2 of 2 or #3 of 3 with "typical, unremarkable volume"), reinforcing that its competitive footprint is concentrated in Medicare COVID testing.
The billing pattern and code mix (a massive volume of low‑unit‑price COVID self‑tests via K1034 coupled with small volumes of pharmacogenomic and HLA assays) imply an operational model reliant on very high claim counts at low per‑claim reimbursement on Medicare (K1034 shows $12 avg paid/claim) and minimal Medicaid scale (K1034 Medicaid shows $1 avg paid/claim). That revenue structure would be sensitive to changes in COVID test reimbursement or demand, while the specialty genetic testing lines appear as low‑volume, supplementary services.
The provider’s NPI was enumerated on 2021-09-30 (~5 years ago), indicating a relatively recent enrollment coincident with the COVID‑19 pandemic period; this timing is consistent with the emergence of a high‑volume COVID self‑test billing profile and suggests the organization either launched or significantly scaled operations in response to pandemic testing demand.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,518,240 | $10 | $18.2M |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 30 | $440 | $13.3K |
| 81306 | The lab analyst performs the technical lab test to detect the presence of specific changes in the nudix hydrolase 15 gene (NUDT15). The test specifically targets common genetic variants such as *2,… | 30 | $290 | $9.2K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 30 | $290 | $8.9K |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 30 | $170 | $5K |
| 81328 | The lab analyst performs the technical lab test to detect the presence of specific changes in the solute carrier organic anion transporter family, member 1B1 (SLCO1B) gene for common variants, such… | 30 | $170 | $5K |
| 81335 | The lab analyst performs the technical lab test to detect the presence of specific changes in the thiopurine S–methyltransferase (TPMT) gene for common variants, such as *2, *3. | 30 | $170 | $4.8K |
| 81381 | The lab analyst performs the technical lab test for high resolution assessment of human leukocyte antigen genes, called HLA, for one Class I allele or allele group of interest, typically one that is… | 30 | $170 | $4.3K |
| 81231 | The lab analyst performs the technical lab test to analyze the common variants of the cytochrome P450 family 3 subfamily A member 5 gene (CYP3A5), such as *2, *3, *4, *5, *6, *7. | 20 | $170 | $3.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 9 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 150 | $50 | $7.1K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 20 | $180 | $3K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,410 | $1 | $2.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 150 | $20 | $2.2K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 20 | $120 | $2K |
| 81306 | The lab analyst performs the technical lab test to detect the presence of specific changes in the nudix hydrolase 15 gene (NUDT15). The test specifically targets common genetic variants such as *2,… | 20 | $120 | $2K |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 20 | $70 | $1.2K |
| 81231 | The lab analyst performs the technical lab test to analyze the common variants of the cytochrome P450 family 3 subfamily A member 5 gene (CYP3A5), such as *2, *3, *4, *5, *6, *7. | 20 | $70 | $1.2K |
| 81328 | The lab analyst performs the technical lab test to detect the presence of specific changes in the solute carrier organic anion transporter family, member 1B1 (SLCO1B) gene for common variants, such… | 20 | $70 | $1.2K |
| 81335 | The lab analyst performs the technical lab test to detect the presence of specific changes in the thiopurine S–methyltransferase (TPMT) gene for common variants, such as *2, *3. | 20 | $70 | $1.2K |
Showing 1–10 of 16
How this provider's Medicaid billing volume and revenue compare to other Ohio providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Ohio median
16 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81381 | The lab analyst performs the technical lab test for high resolution assessment of human leukocyte antigen genes, called HLA, for one Class I allele or allele group of interest, typically one that is… | 4 | 10 | 1,140 | $40 | $3.4M |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 5 | 10 | 80 | $40 | $2.7M |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 5 | 10 | 90 | $30 | $2M |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 3 | 10 | 260 | $10 | $1.5M |
| 81230 | The lab analyst performs the technical lab test to analyze the common variants of the cytochrome P450 family 3 subfamily A member 4 gene (CYP3A4), such as *2, *22. | 3 | 10 | 260 | $10 | $1.4M |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 9 | 30 | 1,080 | $70 | $1.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 108 | 140 | 1,130 | $90 | $1.1M |
| 81291 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for 5,10–methylenetetrahydrofolate reductase, also known as MTHFR. | 5 | 10 | 140 | $10 | $282.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 99 | 120 | 1,000 | $20 | $136K |
| 81241 | The lab analyst performs the technical lab test to detect the presence of a common change, called the Leiden variant, in the gene for coagulation factor V, also known as Factor V Leiden or F5. | 10 | 10 | 120 | $20 | $9.8K |
Showing 1–10 of 16
Other providers in the same ZIP code as Aura Genetics Of Ohio, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Southerncare, Inc. | OH | Community Based Hospice Care Agency | $0 | $42.5M |
| Mercy Health Youngstown LLC | OH | General Acute Care Hospital | $0 | $36.6M |
| The Surgery Center At Southwoods, LLC | OH | Special Hospital | $0 | $20.2M |
| Homecare With Heart, LLC | OH | Home Health Agency | $0 | $19.5M |
| Kids Choice LLC | OH | Speech-Language Pathologist | $0 | $9.7M |
| Sacred Arms, Inc. | OH | Home Health Agency | $0 | $8.4M |
| Valley Home Health Care, LLC | OH | Home Health Agency | $0 | $7.6M |
| Travco Behavioral Health, Inc. | OH | Mental Health Counselor | $0 | $7.3M |
| Triad Health Services, LLC | OH | Plastic Surgery Physician | $0 | $6.9M |
| Vpa PC | OH | Portable X-ray and/or Other Portable Diagnostic Imaging Supplier | $247.6K | $1.3M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.